Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metoprolol tartrate
Drug ID BADD_D01447
Description Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative.[T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
Indications and Usage Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.[A175141] Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.[A175141] All the indications of metoprolol are part of cardiovascular diseases. These conditions correspond to a number of diseases that involve the function of the heart and blood vessels. The underlying causes of these conditions are variable and can be due to genetic disposition, lifestyle decisions such as smoking, obesity, diet, and lack of exercise, and comorbidity with other conditions such as diabetes. The cardiovascular diseases are the leading cause of death on a global scale.[L5533]
Marketing Status approved; investigational
ATC Code C07AB02
DrugBank ID DB00264
KEGG ID D00601
MeSH ID D008790
PubChem ID 441308
TTD Drug ID D0I2MK
NDC Product Code 72888-006; 72888-101; 57451-1163; 65862-063; 30698-459; 36000-033; 50090-1979; 51662-1365; 52817-358; 55154-4451; 55154-5356; 55154-5512; 55700-646; 58118-0361; 60760-243; 60760-295; 60760-566; 63187-532; 0378-4594; 68071-2783; 68788-7832; 68788-8249; 70882-132; 70934-351; 70934-719; 71205-701; 71335-0607; 71335-1600; 71335-2164; 71335-9745; 76420-054; 82727-001; 65862-064; 42708-147; 50090-6083; 51079-801; 55154-4745; 57237-100; 57664-506; 58118-1062; 0378-4593; 67296-0729; 68071-3337; 71335-0743; 71335-1157; 71335-9716; 71872-7124; 71872-7225; 71872-7226; 72611-740; 52423-0915; 52932-0710; 43063-927; 43063-938; 0143-9873; 51407-110; 51655-281; 52817-362; 53808-1117; 57664-162; 63187-609; 0378-0032; 0409-2016; 70882-133; 70934-500; 71335-0241; 71335-1146; 71610-137; 71610-556; 55154-1557; 55154-4752; 63187-174; 68645-190; 70518-3475; 71610-184; 0615-8016; 71872-7283; 65862-062; 50090-5070; 51407-111; 51655-514; 53002-1005; 55154-2126; 63187-252; 63187-600; 70934-736; 71610-147; 71872-7155; 72888-005; 51655-534; 52817-360; 53002-1026; 57664-167; 57664-477; 61919-415; 62584-267; 63187-103; 63629-8101; 67544-387; 68071-2757; 68071-4755; 68788-8207; 68788-8211; 70518-2193; 70518-2437; 71335-0192; 71610-186; 62991-2897; 65862-416; 72640-016; 35356-782; 42708-041; 50090-2149; 50090-2207; 51662-1478; 57237-102; 57664-166; 62584-266; 68071-4880; 68083-131; 68788-7690; 71610-138; 72888-004; 12666-0009; 38779-0578; 30698-458; 49999-575; 51079-255; 51655-884; 52817-359; 63629-8103; 0378-0018; 68071-2877; 68071-5236; 0409-1778; 68645-191; 70518-2615; 71335-1142; 71610-158; 71610-443; 72888-023; 51552-0915; 52932-0743; 63415-0022; 42708-110; 43063-821; 55154-4790; 57237-101; 62584-265; 0378-0047; 70518-0381; 70518-3293; 70518-3503; 70934-390; 71610-080; 71610-565; 72266-122; 0904-7118; 49452-4718; 51927-2697; 50090-0489; 51407-109; 51655-527; 60760-524; 63187-314; 63323-660; 68788-7548; 70518-2024; 70518-3291; 70518-3606; 71335-2064; 71610-559; 0615-8017; 0615-8322; 82727-002; 42419-009; 52817-361; 55289-382
UNII W5S57Y3A5L
Synonyms Metoprolol | Toprol | Betaloc | Betaloc-Astra | Betaloc Astra | Betalok | CGP-2175 | CGP 2175 | CGP2175 | H 93-26 | H 93 26 | H 9326 | Metoprolol Tartrate | Seloken | Spesicor | Spesikor | Metoprolol Succinate | Metoprolol CR-XL | Metoprolol CR XL | Toprol-XL | Toprol XL | Beloc-Duriles | Beloc Duriles | Lopressor
Chemical Information
Molecular Formula C34H56N2O12
CAS Registry Number 56392-17-7
SMILES CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(C(C(=O)O)O)(C(=O )O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Respiratory distress22.02.01.012--Not Available
Retroperitoneal fibrosis20.06.01.006; 10.02.01.026; 07.07.03.003--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Sleep disorder19.02.04.001--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Arterial insufficiency24.04.02.005--Not Available
Neuropsychological test abnormal13.07.06.001--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
The 3th Page    First    Pre   3    Total 3 Pages